Ferring holds infertility treatment lecture, launches Menopaur
Ferring Pharmaceuticals, a research-driven specialty biopharmaceutical group headquartered in Switzerland, has pledged its commitment to collaborating with stakeholders in the healthcare sector, especially those in reproductive health, to give them more options and add more value to their practice.
In view of this, the company recently held two scientific lectures on current trends in infertility treatment in Lagos and Abuja.
Speaking with Pharmanews in an exclusive interview during the Lagos lecture, held at Oriental Hotel, Victoria Island and chaired by the renowned Prof. Osato Giwa-Osagie, coordinator, Assisted Fertility Centre, Lagos University Teaching Hospital, (LUTH), Pharm. Yemi Aladeniyi, sales manager,Nigeria/Ghana, Ferring Pharmaceuticals, said the company was committed to improving the health of Nigerians.
On the launch of Menopaur, a product indicated for the treatment of women undergoing assisted reproduction, Pharm. Aladeniyi said the product, along with some other Ferring’s products, had been in use in Nigeria before now and sold by distributors.
He, however, noted that Ferring had come to wholly handle the marketing and distribution of its products, adding that the company intends to grow with the Nigerian pharmaceutical market irrespective of the challenges facing the business environment in the country.
Menopaur, he said, is a highly purified menopausal gonadotrophin containing a 1:1 ratio of follicle stimulating hormone (SFH) and has been in the global markets for more than 15 years and available in more than 120 countries worldwide.
Ferring, Pharm. Aladeniyi, said is an innovative company with a successful track record in the field of reproductive health, having been involved in developing hormonal treatments for over 65 years and consistently shown commitment to research to help more patients become parents.
Aside developing and marketing products of reproductive health, Ferring also has products in urology, gastroenterology, endocrinology and orthopaedics, he said.
When asked why Ferring organised the scientific lectures, Pharm. Aladeniyi said the company is committed to providing medical education and building capacity to support professionals willing to improve their practice. This, he said, prompted the company to bring a renowned expert in the field of fertility treatment from Vrije Universiteit Brussel, Belgium, Prof. Peter Platteau to Nigeria to share his experience on the use of different treatment approaches with IVF specialists and gynecologists.
The scientific lectures, he disclosed, are the first of many more similar educative programmes that will be organised by Ferring, noting that the company is determined to be in Nigeria for the long haul and to contribute to the development of the health care sector.
Also, speaking at the Lagos lecture, Prof. Giwa-Osagie urged Ferring to make Menopaur available to fertility clinics in Nigeria and give the clinics good rate for bulk purchase, saying that this would help moderate the price for patients.
Prof. Giwa-Osagie also said that with about 45 IVF clinics in Nigeria which is more than all the IVF clinics in the whole of the rest of West Africa added together, Ferring has come to the right market for Menopaur.
Other dignitaries at the lecture included Dr Faye Iketubosin, president, Association for Fertility and Reproductive Health in Nigeria (AFRH); Prof. Oladapo Ashiru, a renowned fertility expert and Pharm. Ramatu Momodu, deputy director, NAFDAC, among others.